Insmed Inc
Q1 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +6.73%.
Did INSM Beat Earnings? Q1 2025 Results
Insmed delivered a mixed first quarter for 2025, topping revenue expectations while falling short on the bottom line as heavy pre-launch spending weighed on profitability. The company posted revenue of $92.82 million, edging past the $92.09 million consensus by 0.80% and marking 22.9% year-over-year growth driven entirely by its sole commercial product, ARIKAYCE, which posted double-digit gains across all three regions for the sixth consecutive quarter. Earnings per share came in at a loss of $1.42, missing the consensus estimate of $1.36 by 4.36%, as the net loss widened to $256.58 million from $157.09 million a year ago; SG&A expenses surged to $147.54 million from $93.10 million as Insmed scaled commercial infrastructure ahead of brensocatib's anticipated U.S. launch. With an FDA PDUFA date of August 12, 2025 for bronchiectasis and regulatory reviews underway in Europe and the U.K., the spending surge reflects a calculated bet on that pipeline asset. Insmed reiterated full-year 2025 ARIKAYCE guidance of $405 million to $425 million, implying 11-17% growth, and ended the quarter with approximately $1.20 billion in cash.
- Double-digit ARIKAYCE growth in all three commercial regions for sixth consecutive quarter
- Ex-U.S. strength driven by increased new patient starts in Japan and Europe
- Consistent cost of product revenues as a percentage of revenues (~22.9%) in line with historical levels
“In the first quarter of 2025, Insmed demonstrated executional excellence across our commercial and clinical programs, while simultaneously preparing for critical near-term milestones, including our Phase 2 data readout of TPIP in PAH, and our anticipated FDA approval of brensocatib for bronchiectasis.”
Insmed CEO, on the earnings call
Forward Guidance & Outlook
Insmed reiterated full-year 2025 global ARIKAYCE revenue guidance of $405 million to $425 million, representing 11-17% year-over-year growth compared to 2024. The company expects brensocatib's FDA review to conclude by the August 12, 2025 PDUFA date, with immediate U.S. launch planned if approved, and anticipates sales growth to accelerate faster than spending following the brensocatib launch. Key upcoming data catalysts include TPIP Phase 2b PAH topline data in June 2025, BiRCh Phase 2b brensocatib CRSsNP topline results by year-end 2025, Phase 3 ENCORE ARIKAYCE topline readout in the first half of 2026, and CEDAR Phase 2b interim futility analysis in the first half of 2026. The company noted anticipated single-digit million dollar annual tariff impact based on current tariffs and plans to expand U.S. manufacturing for brensocatib. U.S. gross-to-net for ARIKAYCE is expected in the high-teens to low-twenties percent range for full-year 2025.
INSM YoY Financials
INSM Revenue by Segment
INSM Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.